The effect of six weeks' treatment with inhaled terbutaline (1 mg four times a day), optimised doses of theophylline (twice a day), the combination of theophylline and terbutaline, and placebo was studied in a randomised, double blind, crossover trial. Thirty patients with partially reversible chronic airflow obstruction and a mean forced expiratory volume in one second (FEV1) 
Though some studies on combination bronchodilator treatment have shown that at least an additive effect is achieved when a beta2 agonist and a methylxanthine are given together,' 2 there is still controversy about this. In patients with chronic obstructive airways disease in one study treament with inhaled metaproterenol for one week produced significant improvement in spirometric values, exercise tolerance, and subjective symptoms, whereas treatment with theophylline did not.3 There was no benefit from combining the two drugs. Dull and hence be more likely to develop side effects. Guyatt et al7 studied the effects of oral theophylline, inhaled salbutamol, and the combination on airway function, exercise capacity, and quality of life, in patients with chronic obstructive airways disease. They observed similar improvement with the two drugs and additional benefit when the drugs were combined. When Taylor et al' studied oral theophylline, inhaled salbutamol, and a combination of the two in patients with chronic obstructive airways disease over three weeks they found that "treatment failures" (non-infective exacerbations of airflow obstruction) were fewest with combined treatment and most with salbutamol, theophylline being intermediate.
In view of the controversy about the relative efficacies of oral theophylline, inhaled beta2 agonists, and their combinations we carried out a randomised, double blind, placebo controlled crossover study in patients with partially reversible chronic obstructive airways disease to assess the relative efficacies of optimal doses of oral theophylline, inhaled terbutaline, a combination of the two drugs, and placebo in keeping them symptom free and improving in lung function for the six weeks of each regimen.
Patients
Thirty seven men, aged 55-85 years, attending the chest clinic at Repatriation General Hospital for regular review of their chronic obstructive airways disease were included in the study. Ten patients were smokers and 27 ex-smokers. The criteria for inclusion in the study were (a) best postbronchodilator value for FEV, in the past two years less than 65% of predicted normal; (b) an improvement of over 15% in FEV, after a bronchodilator aerosol on two previous occasions in the past six months; and (c) the need for regular bronchodilator treatment for optimal symptom control. On entry into the study all patients were taking inhaled beclomethasone and beta2 agonists; 34 patients were taking ipratropium bromide (withdrawn when they entered the study), 28 All patients had received treatment with theophylline previously or were currently receiving it and all had been able to tolerate treatment with it. Those patients receiving theophylline on inclusion into the study were asked to stop taking it for three days. All patients then entered a preparatory period during which the dose of oral theophylline was openly titrated to achieve a steady state peak serum theophylline level of 12-20 mg/litre between five and six hours after ingestion of sustained release theophylline. All patients were capable of inhaling properly from a metered dose aerosol. During this preparatory period, the patients practised measuring and recording their peak expiratory flow rate, and charting medication intake on a daily record card.
PROTOCOL
After the preparatory period there was a two week washout. Patients were then allocated to receive, in a double blind manner, a sequence of four consecutive treatments, each for a period of six weeks, according to 4 x 4 Latin square design. During each treatment period the patient took four puffs of a metered dose inhaler four times daily at 0800, 1400, 1800, and 2200 hours and individualised tablets twice daily at 0800 and 1800 hours. The four treatments consisted of the following: (1) Placebo tablets plus 1 mg inhaled terbutaline from a metered dose canister (250 ,ug/puff) fitted with a tube spacer of 150 ml volume (Bricanyl Misthaler), four times daily; (2) sustained release theophylline tablets (Theodur), twice daily, and placebo for terbutaline aerosol with Misthaler; (3) sustained release theophylline tablets, twice daily, plus 1 mg terbutaline aerosol, four times daily; (4) placebo tablets plus placebo inhaler.
For the four daily terbutaline or placebo inhalations the patients were instructed first to exhale to residual volume, then to activate the device, and then inhale to total lung capacity with breath holding for five seconds after each inhalation. The dose of theophylline was the one determined for that subject during the perparatory period to produce a steady state theophylline concentration in the range 12-20 mg/l 5-6 hours after administration.
Patients receiving treatment with inhaled beclomethasone or oral corticosteroids were allowed to continue treatment with these drugs at a constant dosage throughout the study; ipratropium bromide was not allowed. within 24 hours of this contact and if this additional treatment was considered necessary because of a non-infective exacerbation of airflow obstruction the treatment regimen was deemed a "treatment failure." When a patient developed an exacerbation of airflow obstruction due to a chest infection, the study was suspended until he recovered, and resumed two weeks after recovery. We emphasised that all patients should continue to take the study medications as prescribed until they were assessed. On the day of assessment additional treatment with salbutamol was not permitted, so that the patient's lung function better reflected the response to the allocated treatment. The FEV1 and VC data reported are those obtained at the end of six weeks of treatment when this was completed without failure, or values obtained at the time of onset of failure when this was less than six weeks. Treatment with the next combination of drugs was then started after six weeks (a shorter period when treatment failure occurred).
The protocol was approved by the ethics committee of the Repatriation General Hospital and written consent for the study was obtained from each patient before entry into the study. 
Results
The mean (SD) age of the 30 patients who completed the study was 70 (4 8) years. The daily dose of theophylline ranged from 400 to 1200 mg/day. The mean serum theophylline concentration at the end of the preparatory period five to six hours after ingestion of tablets was 14X02 (126) (range 11-5 to 17-4) mg/I.
TREATMENT FAILURES
The number of "treatment failures" during treatment with placebo and theophylline did not differ (table) . There were fewer failures during treatment with inhaled terbutaline than during treatment with placebo or theophylline alone. Treatment with terbutaline and theophylline combined was significantly better in preventing treatment failure than either drug alone or placebo.
PEF
Mean values of morning and evening PEF during the four treatment periods 15 minutes after the study medications were higher during all active treatments than during placebo treatment (table), being highest with the two drugs combined, followed by terbutaline alone, theophylline alone being the worst of the active treatments (p < 0 01).
FEV, AND VC
The mean FEV, during treatment with the two drugs combined was significantly higher than that during treatment with either drug alone or placebo ( tMean readings for the duration of the treatments.
FEV, values during treatment with theophylline and terbutaline alone were significantly higher than those observed after treatment with placebo. There was no significant difference in mean VC between the combined treatment and terbutaline alone; otherwise the results for VC were similar to those for FEV,. 
Discussion
The results of this study show that in patients with partially reversible chronic obstructive airways disease treatment with a combination of oral theophylline and inhaled terbutaline was most effective in keeping the patient symptom free. Inhaled terbutaline was effective in 60% of patients whereas oral theophylline alone was not superior to placebo in preventing "treatment failure" as defined by the need for additional inhaled beta2 agonist drugs. The concept of "treatment failure" as the most important end point in assessing the efficacy of different regimens was used in this study because, if a particular form of treatment is to be clinically acceptable, it shoud be effective enough to keep patients free of exacerbations of airflow obstruction apart from those due to respiratory infection.
In this study patients received four puffs (1-0 mg) of terbutaline daily, using a spacer device to improve drug delivery-a dose equivalent to more than the two puffs of salbutamol used by previous workers.78 In patients with severe airflow obstruction two puffs from a metered aerosol may not produce a response on the plateau of the dose-response curve9; four puffs will get closer to the plateau than two puffs. With preventing "treatment failures" in most of our patients.
In most studies looking -at the effect of bronchodilators in patients with chronic obstructive airways disease the emphasis is on the effect of the drug on lung function during the study. We believe this is not the most appropriate measurement because in our study, though there were no significant differences in FEV, or VC between treatment with terbutaline and with theophylline, there were significant differences in the number of treat Our study suggests that for patients with partially reversible chronic obstructive airways disease treament with theophylline alone is not justified because of the high incidence of treatment failure. We recommend that treatment should initially be given with an inhaled sympathomimetic agent in a dose higher than is currently recommended. If an adequate response is not achieved additional treatment with theophylline should be tried to determine whether the desired improvement can be achieved.
We 
